Gene

QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

Retrieved on: 
Tuesday, February 27, 2024

This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery.

Key Points: 
  • This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery.
  • QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources.
  • QIAGEN Biomedical KB-AI provides the most complete picture of biomedical relationships, including edge cases and novel relationships.
  • While QIAGEN Biomedical KB-HD is manually curated and known for its high quality and accuracy, QIAGEN Biomedical KB-AI contains over 25x more relationships, allowing data scientists to generate new insights.

QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification

Retrieved on: 
Tuesday, February 27, 2024

QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources.

Key Points: 
  • QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources.
  • It identifies and extracts causal relationships between genes, diseases, drugs and other biological entities with AI, generating over 600 million more biomedical relationships than its complement, QIAGEN Biomedical KB-HD.
  • QIAGEN Biomedical KB-AI provides the most complete picture of biomedical relationships, including edge cases and novel relationships.
  • While QIAGEN Biomedical KB-HD is manually curated and known for its high quality and accuracy, QIAGEN Biomedical KB-AI contains over 25x more relationships, allowing data scientists to generate new insights.

GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

Retrieved on: 
Tuesday, February 27, 2024

Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.

Key Points: 
  • Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.
  • The preclinical study aimed to assess the impact of various combinations of the neuroprotective therapeutic in a preclinical model.
  • “We are excited to finally receive the positive results from our preclinical study, which was our first step in validating our novel, cannabinoid based therapeutic,” said Aitan Zacharin, GCANRx CEO.
  • To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

Cerevance Announces Presentation at AD/PD™ 2024 International Conference

Retrieved on: 
Tuesday, February 27, 2024

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.
  • Overview: The NETSseq platform produces deep transcriptomic and epigenomic profiles from post-mortem human brain tissue.
  • One of these genes, KCNK10, is specifically expressed in astrocytes and oligodendrocytes, and its role in regulating glutamate uptake has been validated.
  • Therapeutic Targets, Mechanisms for Treatment: Astroglia; Poster Shift 2: Friday, March 8 - Saturday, March 9, 2024

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, February 26, 2024

(the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Key Points: 
  • (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
  • Financial results for the quarter ended December 31, 2023:
    Cash, cash equivalents, and investments totaled $594.1 million on December 31, 2023.
  • The Company recorded net product revenue of $42.1 million from sales of VYJUVEK during the quarter ended December 31, 2023.
  • For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the Securities and Exchange Commission.

Immix Biopharma 12 Month Review Progress Update

Retrieved on: 
Wednesday, February 21, 2024

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.

Key Points: 
  • LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.
  • “The past 12 months have seen landmark achievements for Immix Biopharma, cementing our position as a leading cell therapy company in autoimmune disease.
  • NXC-201 is the first and only ‘Single-Day CRS‘ CAR-T, a critical advancement for autoimmune diseases like AL Amyloidosis,” said Ilya Rachman, MD PhD CEO Immix Biopharma.
  • As we reflect on the last 12 months of progress, we wish to connect with you offering an update on Immix Biopharma.

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

Retrieved on: 
Thursday, March 7, 2024

The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.

Key Points: 
  • The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.
  • Central to the success of BioStrand's Foundation AI Model is its utilization of its patented HYFT technology, a sophisticated framework designed to identify and leverage universal fingerprint™ patterns across the biosphere.
  • The Advanced Foundation AI model employs a distinctive approach known as "LLM stacking" to intelligently combine different LLMs, with the HYFTs linked to specific features found in various LLMs.
  • Our presentation will focus on introducing our groundbreaking Universal Foundation AI Model for Multiscale Biological Data Integration.

Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project

Retrieved on: 
Wednesday, March 6, 2024

Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.

Key Points: 
  • Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.
  • This milestone advancement was one of the primary early goals of the mammoth project, and supports the feasibility of future multiplex ex utero mammoth gestation.
  • Invaluable for Colossal’s Woolly Mammoths, these cells can be multiplex-edited and differentiated to study cold adaptation traits like woolly hair growth and fat storage in cellular and organoid models.
  • “In the past, a multitude of attempts to generate elephant iPSCs have not been fruitful.

Carolina Partners with ChristianaCare Gene Editing Institute to Launch CRISPR in a Box™ Kits for High School Science Labs

Retrieved on: 
Tuesday, March 5, 2024

Leading school science supplier Carolina Biological Supply Company announced an exclusive partnership with the ChristianaCare Gene Editing Institute to manufacture and distribute an affordable CRISPR in a Box™.

Key Points: 
  • Leading school science supplier Carolina Biological Supply Company announced an exclusive partnership with the ChristianaCare Gene Editing Institute to manufacture and distribute an affordable CRISPR in a Box™.
  • Educators are invited to see downloadable images of the kit components, classroom use and company leaders on the Gene Editing Institute’s website .
  • “Carolina is proud to partner with the Gene Editing Institute to bring cutting-edge biotechnology into the hands of students,” said Mark Meszaros, vice-president, Core Product Management and Innovation, at Carolina Biological.
  • The Gene Editing Institute , a wholly owned subsidiary of ChristianaCare, is a worldwide leader in CRISPR gene editing technology and the only institute of its kind based within a community health care system.

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.